デフォルト表紙
市場調査レポート
商品コード
1020423

癌の分子診断薬市場- 成長、動向、COVID-19の影響、および予測(2021年~2026年)

Oncology Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 105 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
癌の分子診断薬市場- 成長、動向、COVID-19の影響、および予測(2021年~2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 105 Pages
納期: 2~3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

癌の分子診断の市場規模は、予測期間中に12 %以上のCAGRで拡大すると予測されています。

COVID-19のパンデミックは、癌の分子診断市場に大きな影響を与えています。AMP(Association for Molecular Pathology)が2021年に世界の163の検査室を対象に行った調査によると、回答者の85%が2020年4月から6月の間に癌の分子診断が減少したと回答しています。さらに、回答者の半数以上が、臨床試験のための腫瘍検査が、登録者数の減少、出張への消極性、検査実施能力の低下により減少したことを明らかにしました。今回の調査結果は、パンデミックが癌の分子診断検査に長期的な影響を与え続けることも示しています。さらに、癌の研究開発に従事する研究所や大学も、世界各地で活動が停止しています。さらに、世界のいくつかの地域では、さまざまな組織からの研究費の提供が停止されています。

癌の分子診断薬市場の成長は、世界的な癌の罹患率の上昇、診断検査における技術の進歩、ポイントオブケアテストの需要の増加などの要因に大きく起因しています。これらの要因により、癌用分子診断薬の需要が高まっています。

世界的な癌患者数の増加に伴い、診断に対する需要が高まっていることが、癌分子診断薬市場を後押ししています。世界保健機関(WHO)によると、2020年の癌による死亡者数は約1,000万人とされています。また、米国癌協会の2021年の統計によると、2040年までに世界の癌の負担は、新規罹患者数が2,750万人、癌死亡者数が1,630万人に拡大すると予想されています。このような高い数字は、推定される癌の有病率の上昇が、早期診断と予防医学の必要性の高まりに寄与していることを示しています。したがって、前述の要因を考慮すると、癌の分子診断検査の需要は一貫して増加しています。

当レポートでは、癌の分子診断薬市場について調査し、市場の概要とともに、製品タイプ別、技術タイプ別、用途タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 世界的な癌の有病率の上昇
    • 診断検査の技術的進歩
    • ポイントオブケア治療に対する需要の高まり
  • 市場の抑制要因
    • 分子診断検査の高コスト
    • 熟練労働者の不足と厳格な規制の枠組み
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 製品タイプ別
    • 楽器
    • 試薬
    • その他
  • 技術タイプ別
    • ポリメラーゼ連鎖反応(PCR)
    • 等温核酸増幅技術(INAAT)
    • DNAシーケンシングと次世代シーケンシング
    • インサイチュハイブリダイゼーション
    • 質量分析
    • 転写媒介増幅(TMA)
    • チップとマイクロアレイ
    • その他
  • 用途タイプ別
    • 乳癌
    • 前立腺癌
    • 結腸直腸癌
    • 肺癌
    • 血液癌
    • 肝臓癌
    • 子宮頸癌
    • その他
  • エンドユーザー別
    • 病院
    • 診断センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • F-Hoffmann La-Roche Ltd
    • Bayer AG
    • Becton, Dickinson and Company
    • Danaher Corporation(Cepheid)
    • QIAGEN
    • Siemens Healthineers
    • Sysmex Corporation(Sysmex Europe GmbH)
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Veracyte, Inc
    • Agilient Technologies, Inc.(Dako)
    • TBG Diagnostics Limited
    • HTG Molecular Diagnostics, Inc.

第7章 市場機会と動向

目次
Product Code: 72119

The oncology molecular diagnostics market is expected to register a CAGR of more than 12 % during the forecast period.

The COVID-19 pandemic has significantly impacted the oncology molecular diagnostics market. As per the Association for Molecular Pathology (AMP), 2021 survey of 163 laboratories worldwide, 85% of the respondents reported that molecular testing for cancer decreased during April-June 2020. In addition, more than half of the respondents revealed that oncology testing for clinical trials decreased due to lower enrollment, reluctance to travel, and the ability to perform testing. The survey results also indicate that the pandemic will continue to have long-term effects on molecular diagnostic testing for cancer. In addition, laboratories and universities engaged in the research and development of cancer have also witnessed a halt in activities across the globe. Moreover, the government funding from various organizations for the research is also on hold in several regions of the world.

The studied market growth can be largely attributed to the factors such as the rising prevalence of cancer worldwide, technological advancements in diagnostic testing, and increasing demand for point-of-care testing. These factors are leading to increasing demand for oncology molecular diagnostics.

The rising prevalence of cancer cases across the globe is contributing to the increasing demand for diagnosis which is boosting the oncology molecular diagnostics market. According to the World Health Organization (WHO), cancer accounted for approximately 10 million deaths in 2020. In addition, as per the 2021 statistics by the American Cancer Society, by 2040, the global burden of cancer is expected to grow to 27.5 million new cases and 16.3 million cancer deaths. Such high numbers indicate that the estimated rising prevalence of cancer is contributing to the increasing need for early diagnosis and preventive medicine. Thus, in view of the aforementioned factors, the demand for oncology molecular diagnostic tests is consistently increasing.

Also, due to the increasing technological advancements in diagnostic testing, there is a growing usage of molecular diagnostics tests for oncology. Several advancements are being made in cancer genome sequencing, computational analysis, tumor models, and innovative cancer research methods. For instance, Roche Molecular Systems, Inc. developed Cobas EGFR Mutation Test for non-small cell lung cancer patients and received approval from the United States Food and Drug Administration (USFDA) in 2020 and is a real-time PCR test to detect 42 mutations of the epidermal growth factor receptor (EGFR) gene. In addition, in March 2021, Cancer Research UK and Capital Enterprises, and Roche UK have together launched the Cancer Tech Accelerator program. The new initiative will aid researchers to translate their ideas and lifesaving innovations. Thus, in view of the aforementioned factors, the market is anticipated to witness a significant growth over the forecast period.

However, high cost of molecular diagnostic tests, lack of skilled workforce and stringent regulatory framework are some of the factors impeding the market growth.

Key Market Trends

Polymerase Chain Reaction (PCR) is Anticipated to Observe a Significant Growth

Based on technology, polymerase chain reaction (PCR) is anticipated to witness significant growth. Presently, the polymerase chain reaction (PCR) is the most preferred technology for studying cancer. The major factors contributing to the increasing demand for PCR in oncology molecular diagnostics are greater sensitivity, quantification, ease, precision, and reproducibility, better process quality, fast analysis, and lower risk of contamination. It is a sensitive and rapid technique and is ideal for the detection of lymphoid malignancies. Several manufacturers are engaged in developing PCR-based diagnostic instruments and reagents for the detection of cancer. For instance, in June 2021, the AmoyDx Pan Lung Cancer PCR Panel was launched by Amoy Diagnostics Co., Ltd., Riken Genesis Co., Ltd., and Precision Medicine Asia Co., Ltd. It is approved by the Ministry of Health, Labour and Welfare (MHLW) for marketing and production in Japan. Thus, in view of the aforementioned factors, the market is anticipated to grow significantly over the forecast period.

North America is Anticipated to Observe a Significant Growth in Oncology Molecular Diagnostics Market

Within North America, the United States has held major share of the market. The major factors contributing to the market growth are the presence of many market players engaged in manufacturing and expanding the portfolio of instruments and reagents for molecular diagnostic testing. The region also witnesses the presence of well-established healthcare diagnostic facilities. As per a 2020 report by the American Cancer Society, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP) have developed biomarker testing and treatment guidelines. Additionally, the increasing prevalence of cancer in the country is contributing to the oncology molecular diagnostics market in the region. As per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020 and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer with 284,200 cases. These factors are leading to an increased demand for oncology molecular testing in the region. Thus, in view of the aforementioned factors, the market will witness a significant growth in the region over the forecast period.

Competitive Landscape

The oncology molecular diagnostics market is highly fragmented with presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Danaher Corporation (Cepheid), Veracyte, Inc, Abbott Laboratories, F-Hoffmann La-Roche Ltd and Thermo Fisher Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Cancer Worldwide
    • 4.2.2 Technological Advancements in Diagnostic Testing
    • 4.2.3 Increasing Demand for Point-Of-Care Treatment
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Molecular Diagnostic Tests
    • 4.3.2 Lack of Skilled Workforce and Stringent Regulatory Framework
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product Type
    • 5.1.1 Instrument
    • 5.1.2 Reagents
    • 5.1.3 Other Product types
  • 5.2 Technology Type
    • 5.2.1 Polymerase Chain Reaction (PCR)
    • 5.2.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 5.2.3 DNA Sequencing and Next-Generation Sequencing
    • 5.2.4 In-situ Hybridization
    • 5.2.5 Mass Spectrometry
    • 5.2.6 Transcription Mediated Amplification (TMA)
    • 5.2.7 Chips and Microarrays
    • 5.2.8 Other Technology Types
  • 5.3 Application Type
    • 5.3.1 Breast Cancer
    • 5.3.2 Prostate Cancer
    • 5.3.3 Colorectal Cancer
    • 5.3.4 Lung Cancer
    • 5.3.5 Blood Cancer
    • 5.3.6 Liver Cancer
    • 5.3.7 Cervical Cancer
    • 5.3.8 Other Application Types
  • 5.4 End-User
    • 5.4.1 Hospitals
    • 5.4.2 Diagnostic Centers
    • 5.4.3 Other End-users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 F-Hoffmann La-Roche Ltd
    • 6.1.3 Bayer AG
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Danaher Corporation (Cepheid)
    • 6.1.6 QIAGEN
    • 6.1.7 Siemens Healthineers
    • 6.1.8 Sysmex Corporation (Sysmex Europe GmbH)
    • 6.1.9 Illumina, Inc.
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 bioMerieux SA
    • 6.1.12 Veracyte, Inc
    • 6.1.13 Agilient Technologies, Inc. (Dako)
    • 6.1.14 TBG Diagnostics Limited
    • 6.1.15 HTG Molecular Diagnostics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS